argenx NV ADR (ARGX)vsRoyalty Pharma Plc (RPRX)
ARGX
argenx NV ADR
$892.87
-0.55%
HEALTHCARE · Cap: $54.94B
RPRX
Royalty Pharma Plc
$67.18
+1.90%
HEALTHCARE · Cap: $37.72B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 133% more annual revenue ($5.92B vs $2.54B). RPRX leads profitability with a 32.0% profit margin vs 31.7%. ARGX appears more attractively valued with a PEG of 1.20. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
RPRX
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$892.87
$1674.07 discount
Margin of Safety
-73.5%
Fair Value
$37.37
Current Price
$67.18
$29.81 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 166.0x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
RPRX carries more volatility with a beta of 0.41 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 55/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?